biostudies-literatureBa ZArtificial Intelligence and Information Technology Application Fund of Fuwai Hospital and Chinese Academy of Medical SciencesNoncommunicable Chronic Diseases-National Science and Technology Major ProjectCAMS Innovation Fund for Medical Sciencesthe National High Level Hospital Clinical Research Fundinge105597https://www.ebi.ac.uk/biostudies/studies/S-EPMC12434780biostudies-literatureUnknown15(9)<h4>Introduction</h4>Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care.<h4>Methods and analysis</h4>In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18-85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3 month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence.<h4>Ethics and dissemination</h4>Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1.<h4>Trial registration number</h4>ClinicalTrial, NCT06686056.BMJ openEffectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial.PMC124347802024-I2M-C&amp;T-B-0402023ZD05040002024-GSP-GG-42024-AI222024-I2M-ZH-004Yang LLiu MBa ZLian XChen GYu FZhao WYuan JZhao SZhang XWang XGao XSu YWang ZWu YfalseEffectiveness of an AI-enhanced management system for coronary heart disease (AIM-CHD): rationale and design of a single-centre, open-label, randomised, parallel-controlled trial.<h4>Introduction</h4>Effective secondary prevention of coronary heart disease (CHD) is often hindered by limited healthcare resources and poor patient adherence. We therefore developed an artificial intelligence (AI)-enhanced CHD management platform (AIM-CHD) that (i) automatically captures follow-up data through AI-driven voice calls, optical character recognition of laboratory reports and wearable sensor streams; (ii) enables closed-loop, automated risk factor management; and (iii) dynamically personalises follow-up intensity via continuously updated risk stratification and achievement of treatment targets. This trial aims to evaluate whether AIM-CHD improves risk factor control and reduces cardiovascular events compared with usual care.<h4>Methods and analysis</h4>In this prospective, single-centre, open-label, randomised controlled trial, 1100 CHD patients aged 18-85 years will be enrolled at Fuwai Hospital and randomised 1:1 to either the AIM-CHD group (n=550) or the usual care group (n=550) for a 3 month post-discharge intervention. The primary outcome is low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes include target achievement for LDL-C and blood pressure, as well as glycosylated haemoglobin level, nonsmoking status, body mass index, composite cardiovascular endpoint and medication adherence.<h4>Ethics and dissemination</h4>Ethical approval was approved by the Ethics Committee of Fuwai Hospital on 4 November 2024 (2024-2422). The findings will be disseminated in peer-reviewed publications. An anonymised template of the written informed-consent form (Chinese and English versions) is available as Supplementary Material 1.<h4>Trial registration number</h4>ClinicalTrial, NCT06686056.2025-01-01T00:00:00Z2025 Sep2026-06-01T14:03:07.086Z2026-04-08T13:16:15.386ZS-EPMC124347804095387910.1136/bmjopen-2025-105597